NEW YORK, Dec. 22, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Telix Pharmaceuticals Ltd. (NASDAQ: TLX). Shareholders who purchased shares of TLX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/telix-pharmaceuticals-ltd-loss-submission-form/?id=181002&from=3 CLASS PE ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceutical companies.Allka Research's journey in the investment landscape is marked by a commitment to delivering substantial returns and strategic insights to its clients. In a world filled with complexities, Allka Re ...

Key Takeaways U.S. healthcare challenged the S&P 500 in 2025, with biotech leading as the industry index rose 23.2%. GLP-1 drug breakthroughs, AI-driven efficiency and strong earnings beats fueled the sector's rally. ETF exposure offers diversified access as M&A activity and demographic tailwinds support 2026 growth. As we approach the final weeks of 2025, the U.S. healthcare sector has transitioned from a defensive stalwart to a primary market leader. Evidently, while the S&P 500 has delivered a solid ret ...

Key Takeaways BMRN will acquire all FOLD shares for $14.50 in cash, valuing the deal at $4.8B.The deal adds Galafold and Pombiliti-Opfolda, which added $449M in sales in the first nine months of 2025.BMRN will also gain U.S. rights to a late-stage drug DMX-200 being developed for a rare kidney disease.BioMarin Pharmaceutical (BMRN) announced that it entered a definitive agreement to acquire all outstanding shares of Amicus Therapeutics (FOLD) for $14.50 per share in cash, totaling $4.8 billion.The deal, app ...

We recently published 8 Stocks on Jim Cramer’s Radar.  Eli Lilly and Company (NYSE:LLY) is one of the stocks on Jim Cramer's radars. Eli Lilly and Company (NYSE:LLY) is another top Cramer healthcare stock. Over the course of the year, the CNBC TV host has praised the firm’s lead in the weight loss drug industry and its manufacturing capacity. Cramer has also asserted that Eli Lilly and Company (NYSE:LLY) has a robust drug pipeline that can help the firm in non-weight-loss drug markets. However, more recen ...

Company Overview - Merck & Co., Inc. (NYSE:MRK) has seen its shares increase by 1.9% year-to-date, following a strong performance since early November [2] - Prior to this increase, the stock was down 16.8% year-to-date due to various challenges, including issues in China affecting the Gardasil HPV vaccine shipments and a $3 billion restructuring program [2] Recent Developments - On November 18th, Merck announced a successful phase two trial for its Winrevair drug, which targets patients with combined post- and precapillary pulmonary hypertension, allowing progression to a phase three study [3] - Bank of America raised Merck's share price target to $120 from $105 on December 15th, adjusting its FY27 EPS estimates [3] Market Sentiment - Jim Cramer believes that Merck may be undervalued, describing it as an inexpensive stock amidst a market recovery [3] - Despite the potential of Merck as an investment, there is a belief that certain AI stocks may offer higher returns with limited downside risk [3]

Key Takeaways JNJ has traded above its 50- and 200-day SMAs since June, with a golden cross formed in mid-July.J&J's Innovative Medicine unit delivered organic growth in 2025 despite Stelara's loss of exclusivity.JNJ advanced its pipeline with new approvals and launches, while MedTech showed signs of recovery.Johnson & Johnson’s (JNJ) stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) since the end of June. It achieved the golden cross in mid-July. The 50-day movi ...

PRESS RELEASE AB SCIENCE PATENT FOR MASITINIB IN THE TREATMENT OF SICKLE CELL DISEASE FORMALLY GRANTED IN THE UNITED STATES WITH A PROTECTION UNTIL 2040 THIS DECISION STRENGTHENS MASITINIB’S INTELLECTUAL PROPERTY PORTFOLIO WITH LONG-TERM PROTECTION FOR AN ADDITIONAL INDICATION WITH A HIGH UNMET MEDICAL NEED THE BIOMARKER PHASE 2 IN COOPERATION WITH AP-HP IS FULLY FUNDED Paris, December 22, 2025, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Office has fo ...